Company intelligence / Profile preview

Virax Development

London, United Kingdom

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Virax Biolabs is an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases. The company specializes in developing T-cell testing platforms to provide a comprehensive view of the immune system's response to viruses, moving beyond traditional antibody testing. Their primary platform, ViraxImmune, aims to provide an immunology profiling platform for various viral threats, including COVID-19, Monkeypox, and Hepatitis B. Additionally, the company commercializes diagnostic test kits and personal protective equipment through its ViraxClear and ViraxCare brands to address global health challenges.

Therapeutic areas: Infectious Diseases
Modalities: DiagnosticsIn vitro diagnosticsT-cell testing
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Virax Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virax Development.

Explore the full profile